The study applied the Steno Type 1 Risk Engines, validated prediction models for cardiovascular disease and kidney failure in people with type 1 diabetes, to 3,660 adults with type 1 diabetes who were treated from 2001 to 2016.
SGLT2 inhibitors usage was linked to a 6.1% lower risk of cardiovascular disease over 5 years and with a 5.3% lower risk of kidney failure.
“In our study, we have shown significant risk reductions for cardiovascular disease and kidney failure with SGLT2 inhibitor treatment in type 1 diabetes,” said lead author Elisabeth Stougaard, PhD, of Steno Diabetes Center, in Copenhagen.
READ RELATED: Black People With COVID-19 More Likely to Develop Diabetic Ketoacidosis
“Our model provides an estimate of benefit that may balance the risks associated with use of SGLT2 inhibitors in type 1 diabetes.”
Source: Medindia
Source:
